⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 9, 2026ERJ Open ResearchOpen Access

Bosutinib-associated pulmonary arterial hypertension without prior dasatinib exposure

Jayleigh Lim Ibrahim Haydar Art B. Kelleher Orlaith Shinners Vitaliy Mykytiv Ronan Curtin Desmond M. Murphy

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research investigates the association between bosutinib use and the development of pulmonary arterial hypertension, particularly in patients without prior dasatinib treatment.
Analyzed outcomes in patients receiving bosutinib therapy.
Examined cardiopulmonary toxicities related to tyrosine kinase inhibitors.
Bosutinib was associated with a significant increase in the incidence of pulmonary arterial hypertension.
Proposed mechanisms included endothelial dysfunction and disrupted vascular homeostasis.

Implication

Reveals increased pulmonary arterial hypertension linked to bosutinib in patients, suggesting important cardiovascular monitoring.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lim et al. (2026) studied this question.

synapsesocial.com/papers/6a532e624f7abc118adecb32 https://doi.org/10.1183/23120541.00790-2026

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Late Cardiotoxicity from the Tyrosine Kinase Inhibitor, Dasatinib: Pleural Effusions, Pulmonary Arterial Hypertension, and Right Heart Failure2024
2Pulmonary hypertension associated with ponatinib therapyOriginal Research · 2016 · 59 citations
3A63-32 Unintended Consequences of Targeted Therapy: Dasatinib-associated Severe Pulmonary Arterial HypertensionOriginal Research · 2026
4Adverse Respiratory Reactions to Tyrosine Kinase Inhibitors: A Disproportionality Analysis of Spontaneous Reports from European CountriesOriginal Research · 2026 · 1 citations
5Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicitiesreview · 2018 · 134 citations